Skip to main content
Navigate Up
Sign In

Targeted Therapies Extend Overall Survival in Patients with Stage 4 ALK-Positive Lung Cancer

“(Our study) illustrates the benefit of targeted therapy and selecting therapy for a specific genetic makeup,” first author Jose Pacheco, an assistant professor of medicine/medical oncology at CU School of Medicine, said.